Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AXGN vs DCTH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AXGN Captures Overall Composite Edge (33.1 SELL vs 35.9 SELL), While DCTH Leads 4–2 on Growth & Valuation Pillars

AXGN Overall Winner 6-Pillar Tally: AXGN 2 – 4 DCTH Matrix Metrics: AXGN 5 – 5 DCTH

As of Nov 16, 2026, Axogen, Inc. (AXGN) captures the overall head-to-head institutional edge over Delcath Systems Inc (DCTH) on higher Unified Composite conviction (33.1/100 SELL vs. 35.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while DCTH wins 4–2 across the 6-pillar growth and valuation breakdown. AXGN trades at $55.35 (79.3x Forward P/E, -5.2% operating margin) versus DCTH at $19.68 (N/M Forward P/E, 5.2% operating margin).

  • Composite vs. Pillar Nuance: While DCTH currently prints a higher short-term Unified Composite Score (35.9/100 SELL vs. AXGN 33.1/100 SELL), AXGN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 5.2% operating margin) and revenue trajectory (+26.2% vs. +70.7% YoY).
  • Defensive Composite Rating Caution: Although AXGN compares more favorably head-to-head, both AXGN (33.1/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AXGN vs DCTH
AXGN NASDAQ Head-to-Head Winner
Axogen, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$55.35
-1.03% 1D
Market Cap $3.3B
TTM Revenue $267M
Forward P/E 79.3x
Beta / 30D Vol 1.28β · 123% Vol
Unified Composite Score
33.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 70
RSI-14: 69.9 · SMA20: $47.40 · SMA50: $43.42
DCTH NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap $743.8M
TTM Revenue $110M
Forward P/E N/M
Beta / 30D Vol 1.63β · 131% Vol
Unified Composite Score
35.9 / 100 SELL
Tech 50.0 Fund 38.0 Flow 60.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 68.9 · SMA20: $16.43 · SMA50: $15.96

6-Pillar Scorecard Institutional Category Breakdown (AXGN 2 – 4 DCTH)

Columns: Metric · AXGN · DCTH
1. Valuation Multiples AXGN
Forward P/E 79.3x N/M
Trailing P/E 128.2x 133.6x
PEG Ratio N/M 1.60x
EV / Revenue 11.2x 6.3x
2. Growth & Scale DCTH
Revenue Growth (YoY) +26.2% +70.7%
Earnings Growth (YoY) +300.0% +750.0%
TTM Revenue (USD) $267M $110M
Market Cap $3.3B $743.8M
3. Profitability & Quality DCTH
Gross Margin 74.2% 87.6%
Operating Margin -5.2% 5.2%
Net Profit Margin -12.0% 6.0%
Return on Equity (ROE) -10.3% 5.4%
4. Balance Sheet & Cash Flow DCTH
Cash Generation (TTM) $20M $20M
Cash Flow Margin 7.5% 18.3%
Net Cash / Leverage $309M Net Cash $53M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AXGN
Options Structure Phase BREAKOUT BREAKOUT
Current IV / %ile 58.6% (12th %ile) 109.3% (43rd %ile)
Put/Call OI Skew 0.01x (Call-Skewed) 0.11x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat DCTH
OpEx & R&D Intensity 79.4% of Rev ($212M) 82.4% of Rev ($91M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AXGN (5) vs DCTH (5)
Institutional Metric AXGN DCTH Criterion Row Edge
Market Capitalization
Scale
$3.3B $743.8M Larger Scale AXGN
Trailing P/E Ratio
Valuation
128.2x 133.6x Lower Multiple AXGN
Forward P/E Ratio
Valuation
79.3x N/M Lower Multiple AXGN
Revenue Growth (YoY)
Growth
+26.2% +70.7% Higher Growth DCTH
Operating Margin (TTM)
Profitability
-5.2% 5.2% Higher Margin DCTH
Net Profit Margin
Profitability
-12.0% 6.0% Higher Margin DCTH
Return on Equity (ROE)
Capital Efficiency
-10.3% 5.4% Higher ROE DCTH
52-Week Range Position
Momentum
88% ($23–$60) 80% ($8–$23) Stronger Trend AXGN
Beta / 30D Volatility
Risk Regime
1.28β · 123% Vol 1.63β · 131% Vol Lower Realized Risk AXGN
Unified Institutional Score
Composite Signal
33.1 / 100 (SELL) 35.9 / 100 (SELL) Higher Composite DCTH
Trailing 12M Revenue (USD)
Operating Scale
$267M $110M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
74.2% 87.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 11.2x EV/Rev 1.60x PEG · 6.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$20M ($309M Net Cash) $20M ($53M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AXGN +20.12 pp
AXGN: +59.89% · DCTH: +39.77%
3M Horizon DCTH +6.44 pp
AXGN: +10.29% · DCTH: +16.73%
6M Horizon DCTH +45.51 pp
AXGN: +31.95% · DCTH: +77.46%
1Y Horizon AXGN +1.69 pp
AXGN: +130.26% · DCTH: +128.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AXGN Revenue DCTH Revenue AXGN Op. Margin DCTH Op. Margin Margin Leader
FY2018 $80M N/A -24.4% N/A AXGN
FY2019 $110M N/A -29.4% N/A AXGN
FY2020 $110M N/A -20.6% N/A AXGN
FY2021 $130M $0M -20.0% -690.0% AXGN
FY2022 $140M $0M -21.4% -1245.1% AXGN
FY2023 $160M $0M -13.5% -1849.0% AXGN
FY2024 $190M $40M -1.8% -33.4% AXGN
FY2025 $230M $90M -3.5% 0.8% DCTH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AXGN BREAKOUT
135d in phase · OBV ACCUMULATION
Current IV 58.6%
IV Percentile 12th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DCTH BREAKOUT
66d in phase · OBV ACCUMULATION
Current IV 109.3%
IV Percentile 43rd %ile
Put/Call OI Skew 0.11x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AXGN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.3B market capitalization and -5.2% operating margin.
OpEx & R&D Reinvestment 79.4% of Rev ($212M)
90D Engineering Disclosures 0 Published
DCTH Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $743.8M market capitalization and 5.2% operating margin.
OpEx & R&D Reinvestment 82.4% of Rev ($91M)
90D Engineering Disclosures 0 Published

Investor FAQ AXGN vs DCTH Key Questions & Quantitative Answers

As of Nov 16, 2026, Axogen, Inc. (AXGN) captures the overall head-to-head institutional edge over Delcath Systems Inc (DCTH) on higher Unified Composite conviction (33.1/100 SELL vs. 35.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while DCTH wins 4–2 across the 6-pillar growth and valuation breakdown. AXGN trades at $55.35 (79.3x Forward P/E, -5.2% operating margin) versus DCTH at $19.68 (N/M Forward P/E, 5.2% operating margin). Composite vs. Pillar Nuance: While DCTH currently prints a higher short-term Unified Composite Score (35.9/100 SELL vs. AXGN 33.1/100 SELL), AXGN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 5.2% operating margin) and revenue trajectory (+26.2% vs. +70.7% YoY). Defensive Composite Rating Caution: Although AXGN compares more favorably head-to-head, both AXGN (33.1/100 SELL) and DCTH (35.9/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

DCTH leads the Growth & Scale pillar: AXGN posts +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin), compared with DCTH at +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AXGN cumulative revenue shifted +187.5% while DCTH shifted +125.0%. In operating R&D and SG&A reinvestment, AXGN deploys 79.4% of Rev ($212M) (0 90-day corporate R&D disclosures) versus 82.4% of Rev ($91M) (0 disclosures) for DCTH.

AXGN screens cheaper on headline valuation multiples. AXGN trades at 79.3x Forward P/E, 128.2x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (7.5% FCF margin), whereas DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AXGN (-10.3% ROE) versus DCTH (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, AXGN carries 58.6% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.28β · 123% Vol realized risk). By comparison, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.